Tae Ik Chang1,2, Elani Streja1, Melissa Soohoo1, Tae Woo Kim1,3, Connie M Rhee1, Csaba P Kovesdy4,5, Moti L Kashyap6,7, Nosratola D Vaziri1, Kamyar Kalantar-Zadeh1, Hamid Moradi8,9. 1. Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California, Irvine School of Medicine, Orange, California. 2. Department of Internal Medicine, National Health Insurance Service Medical Center, Ilsan Hospital, Goyangshi, Gyeonggi-do, Republic of Korea. 3. Department of Internal Medicine, Soon Chun Hyang University Hospital, Gumi, Republic of Korea. 4. Division of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee. 5. Nephrology Section, Memphis Veterans Affairs Medical Center, Memphis, Tennessee. 6. Atherosclerosis Research Center, Gerontology Section, Geriatric, Rehabilitation Medicine and Extended Care Health Care Group and. 7. Department of Medicine, University of California, Irvine, Orange, California. 8. Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California, Irvine School of Medicine, Orange, California; hamid.moradi@va.gov. 9. Nephrology Section, Veterans Affairs Medical Center, Long Beach, California; and.
Abstract
BACKGROUND AND OBJECTIVES: Elevated serum triglyceride/HDL cholesterol (TG/HDL-C) ratio has been identified as a risk factor for cardiovascular (CV) disease and mortality in the general population. However, the association of this important clinical index with mortality has not been fully evaluated in patients with ESRD on maintenance hemodialysis (MHD). We hypothesized that the association of serum TG/HDL-C ratio with all-cause and CV mortality in patients with ESRD on MHD is different from the general population. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied the association of serum TG/HDL-C ratio with all-cause and CV mortality in a nationally representative cohort of 50,673 patients on incident hemodialysis between January 1, 2007 and December 31, 2011. Association of baseline and time-varying TG/HDL-C ratios with mortality was assessed using Cox proportional hazard regression models, with adjustment for multiple variables, including statin therapy. RESULTS: During the median follow-up of 19 months (interquartile range, 11-32 months), 12,778 all-cause deaths and 4541 CV deaths occurred, respectively. We found that the 10th decile group (reference: sixth deciles of TG/HDL-C ratios) had significantly lower risk of all-cause mortality (hazard ratio, 0.91 [95% confidence interval, 0.83 to 0.99] in baseline and 0.86 [95% confidence interval, 0.79 to 0.94] in time-varying models) and CV mortality (hazard ratio, 0.83 [95% confidence interval, 0.72 to 0.96] in baseline and 0.77 [95% confidence interval, 0.66 to 0.90] in time-varying models). These associations remained consistent and significant across various subgroups. CONCLUSIONS: Contrary to the general population, elevated TG/HDL-C ratio was associated with better CV and overall survival in patients on hemodialysis. Our findings provide further support that the nature of CV disease and mortality in patients with ESRD is unique and distinct from other patient populations. Hence, it is vital that future studies focus on identifying risk factors unique to patients on MHD and decipher the underlying mechanisms responsible for poor outcomes in patients with ESRD.
BACKGROUND AND OBJECTIVES: Elevated serum triglyceride/HDL cholesterol (TG/HDL-C) ratio has been identified as a risk factor for cardiovascular (CV) disease and mortality in the general population. However, the association of this important clinical index with mortality has not been fully evaluated in patients with ESRD on maintenance hemodialysis (MHD). We hypothesized that the association of serum TG/HDL-C ratio with all-cause and CV mortality in patients with ESRD on MHD is different from the general population. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied the association of serum TG/HDL-C ratio with all-cause and CV mortality in a nationally representative cohort of 50,673 patients on incident hemodialysis between January 1, 2007 and December 31, 2011. Association of baseline and time-varying TG/HDL-C ratios with mortality was assessed using Cox proportional hazard regression models, with adjustment for multiple variables, including statin therapy. RESULTS: During the median follow-up of 19 months (interquartile range, 11-32 months), 12,778 all-cause deaths and 4541 CV deaths occurred, respectively. We found that the 10th decile group (reference: sixth deciles of TG/HDL-C ratios) had significantly lower risk of all-cause mortality (hazard ratio, 0.91 [95% confidence interval, 0.83 to 0.99] in baseline and 0.86 [95% confidence interval, 0.79 to 0.94] in time-varying models) and CV mortality (hazard ratio, 0.83 [95% confidence interval, 0.72 to 0.96] in baseline and 0.77 [95% confidence interval, 0.66 to 0.90] in time-varying models). These associations remained consistent and significant across various subgroups. CONCLUSIONS: Contrary to the general population, elevated TG/HDL-C ratio was associated with better CV and overall survival in patients on hemodialysis. Our findings provide further support that the nature of CV disease and mortality in patients with ESRD is unique and distinct from other patient populations. Hence, it is vital that future studies focus on identifying risk factors unique to patients on MHD and decipher the underlying mechanisms responsible for poor outcomes in patients with ESRD.
Authors: Martin R Salazar; Horacio A Carbajal; Walter G Espeche; Marcelo Aizpurúa; Carlos E Leiva Sisnieguez; Betty C Leiva Sisnieguez; Carlos E March; Rodolfo N Stavile; Eduardo Balbín; Gerald M Reaven Journal: J Am Soc Hypertens Date: 2014-08-14
Authors: Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz Journal: N Engl J Med Date: 2005-07-21 Impact factor: 91.245
Authors: Vera Bittner; B Delia Johnson; Issam Zineh; William J Rogers; Diane Vido; Oscar C Marroquin; C Noel Bairey-Merz; George Sopko Journal: Am Heart J Date: 2009-03 Impact factor: 4.749
Authors: Bengt C Fellström; Alan G Jardine; Roland E Schmieder; Hallvard Holdaas; Kym Bannister; Jaap Beutler; Dong-Wan Chae; Alejandro Chevaile; Stuart M Cobbe; Carola Grönhagen-Riska; José J De Lima; Robert Lins; Gert Mayer; Alan W McMahon; Hans-Henrik Parving; Giuseppe Remuzzi; Ola Samuelsson; Sandor Sonkodi; D Sci; Gultekin Süleymanlar; Dimitrios Tsakiris; Vladimir Tesar; Vasil Todorov; Andrzej Wiecek; Rudolf P Wüthrich; Mattis Gottlow; Eva Johnsson; Faiez Zannad Journal: N Engl J Med Date: 2009-03-30 Impact factor: 91.245
Authors: Hamid Moradi; Christina Park; Elani Streja; Donovan A Argueta; Nicholas V DiPatrizio; Amy S You; Connie M Rhee; Nosratola D Vaziri; Kamyar Kalantar-Zadeh; Daniele Piomelli Journal: Am J Nephrol Date: 2020-01-14 Impact factor: 3.754
Authors: Julio Alejandro Lamprea-Montealegre; Natalie Staplin; William G Herrington; Richard Haynes; Jonathan Emberson; Colin Baigent; Ian H de Boer Journal: Clin J Am Soc Nephrol Date: 2019-12-12 Impact factor: 8.237
Authors: Benjamin J Lee; Chi-Yuan Hsu; Rishi V Parikh; Thomas K Leong; Thida C Tan; Sophia Walia; Kathleen D Liu; Raymond K Hsu; Alan S Go Journal: BMC Nephrol Date: 2018-06-11 Impact factor: 2.388